ClinicalIntelPulse · Clinical Pipeline Scan

import { wrapFetchWithPayment } from "@x402/fetch";
import { privateKeyToAccount } from "viem/accounts";

const account = privateKeyToAccount(process.env.PRIVATE_KEY);
const fetchWithPay = wrapFetchWithPayment(fetch, account);

const res = await fetchWithPay("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/pipeline-scan", {
  method: "GET",
});
const data = await res.json();

curl -X GET \
  "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/pipeline-scan?condition=Disease+or+condition+%E2%80%94+e.g.+%22Non-Small+Cell+Lung+Cancer%22+%7C+%22Alzheimer+Disease%22+%7C+%22Type+2+Diabetes%22+%7C+%22Crohn+Disease%22+%7C+%22Multiple+Myeloma%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&phase=phase2+%7C+phase3+%7C+both+%28default%3A+both%29&status=active+%7C+all+%28default%3A+active+%E2%80%94+recruiting+%2B+active+not+recruiting%29" \
  -H "X-PAYMENT: <signed x402 payment>"

{
  "approved_drugs_context": "NSCLC has 30+ FDA-approved agents. Pipeline is additive rather than disruptive in most cases.",
  "geographic_distribution": {
    "asia_pct": 22,
    "europe_pct": 28,
    "most_active_countries": [
      "United States",
      "China",
      "Germany",
      "South Korea",
      "Japan"
    ],
    "other_pct": 5,
    "us_trials_pct": 45
  },
  "mechanism_breakdown": {
    "adc": 18,
    "bispecific": 12,
    "chemo_combinations": 31,
    "io_checkpoint_inhibitors": 62,
    "other": 81,
    "targeted_therapy": 41
  },
  "phase3_highlights": [
    {
      "countries": [
        "United States",
        "Germany",
        "Japan",
        "South Korea"
      ],
      "nctId": "NCT05116748",
      "primaryCompletion": "2026-03",
      "sponsor": "Merck",
      "status": "RECRUITING",
      "title": "Pembrolizumab + Carboplatin vs SOC in NSCLC"
    }
  ],
  "pipeline_assessment": "Extremely crowded pipeline — PD-1/L1 space saturated. ADCs and bispecifics represent highest differentiation potential. KRAS G12C targeted therapies emerging as new standard.",
  "pipeline_totals": {
    "phase2_count": 156,
    "phase3_count": 89,
    "total_active": 245
  },
  "query_summary": {
    "condition": "Non-Small Cell Lung Cancer",
    "phases_searched": [
      "PHASE2",
      "PHASE3"
    ],
    "status_filter": "RECRUITING,ACTIVE_NOT_RECRUITING"
  },
  "sponsor_landscape": {
    "academic_sponsors": "ECOG-ACRIN, Alliance, NCI leading academic cooperative groups",
    "emerging_biotechs": [
      "Turning Point Therapeutics",
      "Blueprint Medicines",
      "Mirati Therapeutics"
    ],
    "top_industry_sponsors": [
      "Roche/Genentech (18 trials)",
      "Bristol-Myers Squibb (14)",
      "AstraZeneca (13)",
      "Merck (12)",
      "Pfizer (11)"
    ]
  }
}